Drug Profile
PK 101 002
Alternative Names: PK-101-002Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator PMG Pharm Co Ltd
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arthritis
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Arthritis(In volunteers) in South Korea
- 24 Apr 2019 PMG Pharm completes phase I trials in Arthritis (In volunteers) in South Korea (NCT03553316)
- 18 Feb 2019 Phase-I clinical trials in Arthritis (In volunteers) in South Korea (unspecified route) (NCT03553316)